newsfilter
← Latest News
PR Newswire·

DURECT Announces 1-for-10 Reverse Stock Split

CUPERTINO, Calif., Nov. 28, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver